INT20239

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1990
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 10
Total Number 11
Disease Relevance 10.98
Pain Relevance 0.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (APOA1) small molecule metabolic process (APOA1) extracellular region (APOA1)
plasma membrane (APOA1) enzyme binding (APOA1) transmembrane transport (APOA1)
Anatomy Link Frequency
plasma 1
coronary artery 1
liver 1
adipocytes 1
APOA1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 5 94.64 High High
Multiple sclerosis 6 89.04 High High
Inflammation 39 88.84 High High
imagery 32 84.36 Quite High
fibrosis 99 83.20 Quite High
agonist 2 75.68 Quite High
Pain 5 45.56 Quite Low
Central nervous system 5 33.52 Quite Low
headache 4 27.76 Quite Low
backache 1 27.00 Quite Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 306 100.00 Very High Very High Very High
Death 20 100.00 Very High Very High Very High
Alzheimer's Dementia 1 99.56 Very High Very High Very High
Hepatitis 4 99.30 Very High Very High Very High
Atherosclerosis 51 99.28 Very High Very High Very High
Injury 8 98.48 Very High Very High Very High
Obesity 78 97.94 Very High Very High Very High
Cardiovascular Disease 58 97.12 Very High Very High Very High
Myocardial Infarction 12 95.68 Very High Very High Very High
Coronary Artery Disease 145 95.44 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
While there was no significant change in apolipoprotein A levels with atorvastatin monotherapy (+1.5%, p = 0.493), there was a small, albeit statistically significant increase in apolipoprotein A levels in the combination therapy group (+4.5%, p = 0.041).
Neg (no) Regulation (change) of apolipoprotein A associated with disorder of lipid metabolism
1) Confidence 0.60 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2803170 Disease Relevance 0.66 Pain Relevance 0
Figure 5 shows that a similar effect is also clearly observed in adipocytes, since an increase of 100 to 500% in the amount of apoE is measured in the culture medium at 6 hours, dependent upon the dose of apoA-I used (from 5 to 20 ?
Regulation (dependent) of apoA-I in adipocytes associated with obesity
2) Confidence 0.36 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC2917427 Disease Relevance 0.31 Pain Relevance 0
Using stratified and multivariate stepwise regression analysis, it was shown that the apo A1, apoB/apoA1 are more sensitive and specific than the ordinary indices (e.g. total cholesterol, triglycerides, LDL-C and HDL-C) in estimating the degree of coronary artery stenosis and the differentiation of CAD from other diseases.
Regulation (sensitive) of apoA1 in coronary artery associated with coronary stenosis, coronary artery disease, disease and disorder of lipid metabolism
3) Confidence 0.26 Published 1990 Journal Zhonghua Xin Xue Guan Bing Za Zhi Section Abstract Doc Link 2128269 Disease Relevance 1.82 Pain Relevance 0.09
Another potential target for raising HDL-C levels is augmenting ApoA-I levels (an important protein in HDL-C).
Regulation (target) of ApoA-I associated with disorder of lipid metabolism
4) Confidence 0.26 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2835557 Disease Relevance 1.01 Pain Relevance 0.07
On logistic regression analysis (Tables 5 and 6), the age- and sex-adjusted OR for the presence of CVD was 2.3 (95% confidence interval [CI], 2.0 to 2.7) and 2.0 (95% confidence interval [CI], 1.6 to 2.4) when apoB levels above 1.26 g/L and apoB/apoA-I ratio values above 1.13 were compared with values below these cut-off points, respectively.
Regulation (values) of apoA-I associated with cardiovascular disease
5) Confidence 0.25 Published 2006 Journal Biomark Insights Section Body Doc Link PMC2716782 Disease Relevance 0.54 Pain Relevance 0.03
The effects on plasma cholesterol, TG, HDL, LDL and apolipoproteins A1 (apoA1), B (apoB) and Lp(a) over 4 weeks daily intake of 2-3 times the normal daily intake of SL were examined.
Spec (examined) Regulation (effects) of apoA1 in plasma associated with disorder of lipid metabolism
6) Confidence 0.14 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2768711 Disease Relevance 0.10 Pain Relevance 0
However, it does not change circulating ApoA1 levels [14].
Neg (not) Regulation (change) of ApoA1
7) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3012070 Disease Relevance 1.80 Pain Relevance 0
Furthermore, there were no significant associations between measures of vascular function or atheroma burden and any of: attained LDL-C; change in LDL-C, HDL-C, apoB, apoA-I, or CRP.


Regulation (change) of apoA-I associated with atherosclerosis and disorder of lipid metabolism
8) Confidence 0.13 Published 2008 Journal Atherosclerosis Section Body Doc Link PMC2292239 Disease Relevance 0.58 Pain Relevance 0.04
It directly regulates ApoA-1, HDL, and amyloid precursor protein (APP; Figure 4).
Regulation (regulates) of ApoA-1 associated with alzheimer's dementia and disorder of lipid metabolism
9) Confidence 0.07 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2730746 Disease Relevance 1.42 Pain Relevance 0.16
In the second case the absolute value of ApoA1 was not decreased (1.72 g/L) but was relatively low in comparison with HDL cholesterol (1.64 mmol/L).
Regulation (value) of ApoA1 associated with disorder of lipid metabolism
10) Confidence 0.06 Published 2006 Journal BMC Gastroenterol Section Body Doc Link PMC1386692 Disease Relevance 1.87 Pain Relevance 0.11
In a mouse model of fulminant hepatitis, intravenous application of siRNA targeting the death receptor CD95 (APO-1/Fas) was capable of preventing liver injury [57].
Regulation (targeting) of APO-1 in liver associated with injury, death and hepatitis
11) Confidence 0.04 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.86 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox